The care of patients with HIV and Burkitt lymphoma poses a challenge to clinicians. Due to the limited treatment options that exist for relapsed/refractory Burkitt lymphoma, there is a need for the development of new therapies. This review aims to discuss evidence for current management strategies including chemotherapy and stem cell transplant, and highlight gaps in knowledge that will need to be addressed in the future.
NavariMEtebariMDe FalcoGet al.
The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma.Front Microbiol2015;
6: 556.
10.
OkiYFanaleMRomagueraJet al.
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol2015;
171: 463–470.
11.
ShenYZhangRLiuLet al.
Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin's lymphoma in Chinese population. Infect Agent Cancer2017;
12: 7.
12.
DozzoMCarobolanteFDonisiPMet al.
Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther2016;
8: 11–29.
13.
HoelzerDWalewskiJDohnerHet al.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: a report of a large prospective multicenter trial. Blood2014;
124: 3870–3879.
14.
IntermesoliTRambaldiARossiGet al.
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Hematologica2013;
98: 1718–1725.
15.
RiberaJMGarciaOGrandeCet al.
Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status. Cancer2013;
119: 1660–1668.
16.
XicoyBRiberaJMMullerMet al.
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma2014;
55: 2341–2348.
17.
DunleavyKPittalugaSShovlinMet al.
Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med2013;
369: 1915–1925.
18.
JacobsonCLaCasceA.How I treat Burkitt lymphoma in adults. Blood2014;
124: 2913–2920.
DunleavyKLittleRFWilsonWH.Update on Burkitt lymphoma. Hematol Oncol Clin North Am2016;
30: 1333–1343.
21.
GriffinTCWeitzmanSWiensteinHet al.
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer2009;
52: 177–181.
22.
SweetenhamJWPearceRTaghipourGet al.
Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma – outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol1996;
14: 2465–2472.
AbedinSMBoddyCSMunshiHG.BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther2016;
9: 5943–5953.
26.
MertzJAConeryARBryantBMet al.
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A2011;
108: 16669–16674.
27.
BoiMGaudioEBonettiPet al.
The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res2015;
21: 1628–1638.
28.
TrabuccoSEGersteinRMEvensAMet al.
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res2015;
21: 113–122.
